Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment

This interventional trial (n=10) will explore the impact of audiovisual stimuli on the tolerability and effectiveness of ketamine/esketamine treatment for depressive episodes.

Sponsored by Yale University, the study aims to provide patients with a serene environment using virtual reality goggles and noise-cancelling headphones and assess whether this intervention enhances treatment outcomes. It’s estimated to start in February 2024 and be completed in October 2024, and it aims to enrol around 10 participants. Participants must be at least 18 years old and have completed the acute series of ketamine/esketamine treatment.

The study will measure various outcomes, including the tolerability and safety of virtual reality treatment, changes in treatment experience satisfaction, and alterations in consciousness states. Dr. Sina Nikayin from the Department of Psychiatry at Yale University is the principal investigator.

Topic Depression
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Yale University
The Yale Psychedelic Science Group was established in 2016.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.